6UH1

Structure of the EVA71 strain 11316 capsid


Experimental Data Snapshot

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.04 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

wwPDB Validation 3D Report Full Report


This is version 1.1 of the entry. See complete history

Literature

Scaffold Simplification Strategy Leads to a Novel Generation of Dual Human Immunodeficiency Virus and Enterovirus-A71 Entry Inhibitors.

Martinez-Gualda, B.Sun, L.Marti-Mari, O.Noppen, S.Abdelnabi, R.Bator, C.M.Quesada, E.Delang, L.Mirabelli, C.Lee, H.Schols, D.Neyts, J.Hafenstein, S.Camarasa, M.J.Gago, F.San-Felix, A.

(2020) J.Med.Chem. 63: 349-368

  • DOI: 10.1021/acs.jmedchem.9b01737
  • Primary Citation of Related Structures:  

  • PubMed Abstract: 
  • Currently there are only three FDA-approved drugs that inhibit HIV entry-fusion into host cells. The situation is even worse for enterovirus EV71 infection for which no antiviral therapies are available. We describe here the discovery of potent entry ...

    Currently there are only three FDA-approved drugs that inhibit HIV entry-fusion into host cells. The situation is even worse for enterovirus EV71 infection for which no antiviral therapies are available. We describe here the discovery of potent entry dual inhibitors of HIV and EV71. These compounds contain in their structure three or four tryptophan (Trp) residues linked to a central scaffold. Critical for anti-HIV/EV71 activity is the presence of extra phenyl rings, bearing one or two carboxylates, at the C2 position of the indole ring of each Trp residue. The most potent derivatives, 22 and 30, inhibit early steps of the replicative cycles of HIV-1 and EV-A71 by interacting with their respective viral surfaces (glycoprotein gp120 of HIV and 5-fold axis of the EV-A71 capsid). The high potency, low toxicity, facile chemical synthesis and great opportunities for chemical optimization make them useful prototypes for future medicinal chemistry studies.



Macromolecules

Find similar proteins by: Sequence  |  Structure

Entity ID: 1
MoleculeChainsSequence LengthOrganismDetails
VP1
A
297Human enterovirus 71Mutation(s): 0 
Find proteins for D4QGA8 (Human enterovirus 71)
Go to UniProtKB:  D4QGA8
Entity ID: 2
MoleculeChainsSequence LengthOrganismDetails
VP2
B
254Human enterovirus 71Mutation(s): 0 
Find proteins for I6W7A3 (Human enterovirus 71)
Go to UniProtKB:  I6W7A3
Entity ID: 3
MoleculeChainsSequence LengthOrganismDetails
VP3
C
242Human enterovirus 71Mutation(s): 0 
Find proteins for A0A0E3SXU7 (Human enterovirus 71)
Go to UniProtKB:  A0A0E3SXU7
Entity ID: 4
MoleculeChainsSequence LengthOrganismDetails
VP4
D
69Human enterovirus 71Mutation(s): 0 
Find proteins for E9RGA0 (Human enterovirus 71)
Go to UniProtKB:  E9RGA0
Small Molecules
Ligands 1 Unique
IDChainsName / Formula / InChI Key2D Diagram3D Interactions
SPH
Query on SPH

Download SDF File 
Download CCD File 
A
SPHINGOSINE
C18 H37 N O2
WWUZIQQURGPMPG-MSOLQXFVSA-N
 Ligand Interaction
Experimental Data & Validation

Experimental Data

  • Method: ELECTRON MICROSCOPY
  • Resolution: 3.04 Å
  • Aggregation State: PARTICLE 
  • Reconstruction Method: SINGLE PARTICLE 

Structure Validation

View Full Validation Report or Ramachandran Plots



Entry History 

Deposition Data

  • Deposited Date: 2019-09-26 
  • Released Date: 2019-12-18 
  • Deposition Author(s): Lee, H., Hafenstein, S.
  • This entry supersedes: 6DIJ

Revision History 

  • Version 1.0: 2019-12-18
    Type: Initial release
  • Version 1.1: 2020-01-22
    Type: Database references